Drugs / 177Lu-Dansyl-PSMA
177Lu-Dansyl-PSMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06377683 | Apr 2024 → Mar 2025 | castration-resistant prostate carcinoma | The First Affiliated Hospital of Xiamen University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-Dansyl-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06377683 ↗ |
| Known as | 177Lu-DansyI-PSMA | “Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer” NCT06377683 ↗ |
| Known as | LNC1011 | “Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer” NCT06377683 ↗ |
| Modality | Other / unclassified | “a long-lasting radiolabeled ligand 177Lu-Dansyl-PSMA” NCT06377683 ↗ |
| Route | Intravenous | “Route of administration: Slow intravenous infusion/injection (i.v.)” NCT06377683 ↗ |